EyePoint Pharmaceuticals
EYPTEYPT · Stock Price
Historical price data
Overview
EyePoint Pharmaceuticals is strategically focused on developing and commercializing innovative, sustained-release therapeutics to address the high treatment burden in serious retinal diseases. Its lead candidate, DURAVYU™ (EYP-1901), a vorolanib-loaded insert, is advancing through pivotal Phase 3 trials for wet AMD and diabetic macular edema (DME), with key data readouts expected in 2026. The company leverages its proprietary, clinically validated Durasert E™ bioerodible delivery platform to create durable treatments that aim to improve patient outcomes and compliance while capturing significant market opportunity.
Technology Platform
Durasert E™ is a bioerodible, sustained-release delivery platform for intravitreal injection, enabling long-acting (≥6 months) drug delivery with a proven safety heritage from four prior FDA-approved products.
Pipeline
20| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Dexycu + Standard of Care post operative eye drops (steroid,... | Cataract | Approved | |
| Dexamethasone + Prednisolone Acetate Ophthalmic | Cataract | Approved | |
| Dexycu | Cataract | Phase 3 | |
| FAI insert + Sham injection | Non-Infectious Uveitis | Phase 3 | |
| Sham Injector + FAI Insert | Uveitis | Phase 3 |
Funding History
3FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
EyePoint competes in the sustained-release retinal therapy space against approved products like Roche's Susvimo™ implant and Regeneron's high-dose aflibercept, as well as numerous clinical-stage programs. Its key differentiators are the in-office injection delivery of its bioerodible Durasert E™ platform and the novel multi-mechanism action of its lead drug, vorolanib.